Haisco Pharmaceutical Group Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hisco" or "Company") was established in 2000 and is a diversified and specialized pharmaceutical group listed company that integrates new drug research and development, production and manufacturing, sales, and other businesses. The company's research and development strength ranks among the top in the chemical pharmaceutical industry, and it is a leading enterprise with the most complete product line in the field of parenteral nutrition. It also holds an important position in sub markets such as liver disease treatment, depression, and anti infection. Hispec has a strong technical force. The R&D center has nearly 800 scientific researchers, including many doctors and masters. At present, the R&D center's scientific research work involves anesthesia and analgesia, diabetes and complications, tumors, neuralgia, parenteral nutrition, cardio cerebrovascular, digestion and respiration and other disease fields. It has launched more than 90 new projects in the fields of innovative drugs and high-end generic medicine. At present, there are a total of 8 Class 1 new drugs under research. The company has independently developed China's first brand new intravenous anesthesia drug with independent intellectual property rights. The Class 1 innovative drug, cyclophenol injection, has been successfully launched. Currently, cyclophenol has been approved for new indications such as "sedation and anesthesia during non tracheal intubation surgery/operation", "induction and maintenance of general anesthesia", and "sedation during intensive care". As of the end of December 2021, cyclophenol has been listed in nearly 400 hospitals in China for one year, with a sales revenue of approximately 60 million yuan. At the same time, in the United States, FDA has approved exemptions for Phase I and Phase II clinical trials to directly conduct Phase III clinical studies, and is currently being enrolled. The R&D center has independent generic drug research buildings, innovative drug research buildings, and pilot bases, equipped with advanced precision research instruments, and experimental conditions at a leading level in China. Since its establishment in 2000, a total of 70 varieties have been successfully developed, of which 22 were first imitated and listed, with a first imitated rate exceeding 31%, and the first imitated success rate ranking at the leading level in the industry; 24 cases were evaluated for consistency through/as if passing. The company has a product layout covering multiple sub fields such as anesthesia and analgesia, parenteral nutrition, tumor antiemesis, liver disease treatment, digestive system, nervous system, and anti infection. Currently, there are 49 varieties, most of which are the first or exclusive imitations in China. The main products include cyclophenol injection, compound amino acid injection (18AA-VII), fat emulsion amino acid (17) glucose (11%) injection, doxazetron mesylate injection, and methylprednisolone sodium succinate for injection Flupentixol melitracin tablets, polyene phosphatidylcholine injection, etc. Hisco has a sound sales network and mature marketing channels, and the company has built a huge sales network covering major provinces and cities across the country based on the guidelines of "self built team, cooperative operation". Guided by the twelve character policy of "medical driven, academic leading, and sales implementation", we adopt a diversified marketing model, innovate pilot projects, and transform from point to area towards refinement, systematization, and platformization. At present, our company has over 1000 sales personnel and nearly 5000 management representatives, covering over 10000 second level and above hospitals. |
| Headquarter | Shannan City |
| Establish Date | 8/26/2005 |
| Listed Code | 002653.SZ |
| Listed Date | 1/17/2012 |
| Chairman | Wang Junmin. |
| CEO | Fan Xiulian. |
| Website | www.haisco.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
